ArticleStem cells international2012
Bilateral transplantation of allogenic adult human bone marrow-derived mesenchymal stem cells into the subventricular zone of Parkinson's disease: a pilot clinical study.
Article in Stem cells international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 4 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Homogenous Cell Transplantation Trials in Parkinson's Disease: A Systematic Review and Meta-Analysis.Movement disorders clinical practice · 2026Pooled it
- Stem cell therapy approaches for non-malignant diseases & non-haematological diseases in India: A systematic review.The Indian journal of medical research · 2024Pooled it
- Cell-therapy for Parkinson's disease: a systematic review and meta-analysis.Journal of translational medicine · 2023Pooled it
- Effect of Bone Marrow Stromal Cells in Parkinson's Disease Rodent Model: A Meta-Analysis.Frontiers in aging neuroscience · 2020Pooled it
- Review
- Review
- Mesenchymal stem cells and the central nervous system: historical perspectives and future directions.Frontiers in molecular neuroscience · 2026Review
- Enhanced susceptibility of porcine muscle-derived mesenchymal stem cells to Aujeszky's virus compared Vero cells.Animal biotechnology · 2025Article
- Therapeutic potential and challenges of mesenchymal stem cells in neurological disorders: A concise analysis.Journal of neuropathology and experimental neurology · 2025Review
- Article
- MRI-guided focused ultrasound for treating Parkinson's disease with human mesenchymal stem cells.Scientific reports · 2025Article
- TGF-β1 mediates hypoxia-preconditioned olfactory mucosa mesenchymal stem cells improved neural functional recovery in Parkinson's disease models and patients.Military Medical Research · 2024Article
- Mesenchymal stem-cell-derived microvesicles ameliorate MPTP-induced neurotoxicity in mice: a role of the gut-microbiota-brain axis.Psychopharmacology · 2023Article
- Combined cell-based therapy strategies for the treatment of Parkinson's disease: focus on mesenchymal stromal cells.Neural regeneration research · 2023Review
- Mechanism of Mesenchymal Stem Cells as a Multitarget Disease- Modifying Therapy for Parkinson's Disease.Current neuropharmacology · 2023Review
- Long-term, repeated doses of intravenous autologous mesenchymal stem cells for a patient with Parkinson's disease: a case report.Frontiers in neurology · 2023Article
- Stem Cell-based and Advanced Therapeutic Modalities for Parkinson's Disease: A Risk-effectiveness Patient-centered Analysis.Current neuropharmacology · 2022Review
- Targeted Therapy for Inflammatory Diseases with Mesenchymal Stem Cells and Their Derived Exosomes: From Basic to Clinics.International journal of nanomedicine · 2022Review
- Cellular and molecular imaging for stem cell tracking in neurological diseases.Stroke and vascular neurology · 2021Review
- Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinson's disease.NPJ Regenerative medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The progress of PD and its related disorders cannot be prevented with the medications available. In this study, we recruited 8 PD and 4 PD plus patients between 5 to 15 years after diagnosis. All patients received BM-MSCs bilaterally into the SVZ and were followed up for 12 months. PD patients after therapy reported a mean improvement of 17.92% during "on" and 31.21% during "off" period on the UPDRS scoring system. None of the patients increased their medication during the follow-up period. Subjectively, the patients reported clarity in speech, reduction in tremors, rigidity, and freezing attacks. The results correlated with the duration of the disease. Those patients transplanted in the early stages of the disease (less than 5 years) showed more improvement and no further disease progression than the later stages (11-15 years). However, the PD plus patients did not show any change in their clinical status after stem cell transplantation. This study demonstrates the safety of adult allogenic human BM-MSCs transplanted into the SVZ of the brain and its efficacy in early-stage PD patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.